menu
    • menu
    [{"orgOrder":0,"company":"Refuge Biotechnologies","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RB-340","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Refuge Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Refuge Biotechnologies \/ Refuge Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Refuge Biotechnologies \/ Refuge Biotechnologies"},{"orgOrder":0,"company":"Refuge Biotechnologies","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Refuge Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Refuge Biotechnologies \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Refuge Biotechnologies \/ Kite Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Refuge Biotechnologies

    Menu

    Refuge Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Refuge Biotechnologies

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Refuge Biotechnologies

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platf...

                            Details : Through this exclusive license agreement with Refuge’s platform, coupled with our unique in-house research capabilities, we aim to create a new generation of CAR T-cell products to induce long-term remissions for more patients.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 20, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Refuge Biotechnologies

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed

                            Refuge Biotechnologies

                            U.S.A arrow
                            BIOHK2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RB-340

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of ...

                            Details : Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : RB-340

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth